isabelobrien, Author at European Medical Journal - Page 41 of 66

FDA nod for Roche and Amgen’s blood testing device

The FDA has granted Breakthrough Device Designation to Roche’s new blood test, developed in collaboration with Amgen, that measures key blood markers of inherited cardiovascular risk.

AZ’s Stefan Woxström on preparing healthcare systems for the future

Stefan Woxström, Senior Vice President Europe and Canada, AstraZeneca, talks about the need for future-proofing healthcare systems, incentivising innovation and reimbursement.

GSK pledges £45m to new antimicrobial resistance initiative

GSK has pledged £45m to the Fleming Initiative, a UK scheme to tackle antimicrobial resistance, led by Imperial College Healthcare NHS Trust and Imperial College London.

Coins falling

Pfizer and AstraZeneca to invest nearly $1bn in France

Pfizer and AstraZeneca have set their sights on France with major investments totalling nearly 1bn (USD) ahead of the country’s annual ‘Choose France’ business summit.

Spotlight: April 2024

Catch up on the top stories to come from the pharma industry over April, including new collaborations set to improve treatments for patients, the latest approvals and more.

Poor return on investment rates on the rise

The pharma industry’s ability to recoup costs on their drug development pipeline was in trouble, been is the downward spiral coming to an end? Read more.

Does pharma have the power to turn back time?

Finding a way to combat the negative effects of ageing could save healthcare systems millions. Learn whether ageing could be the next big pharma market to take the world by storm.

Orphan drugs face new pressures

The orphan drug market has seen robust growth over the past decade, but may face challenges in maintaining its trajectory due to evolving investor and payer preferences.

Roundtable: How can pharma close the gender health gap?

Robyn Widenmaier (GSK) and Tabetha Sundin (AstraZeneca) discuss whether bids to improve gender parity could be the ticket to change in women’s health.

Spotlight: March 2024

Catch up on March’s top pharma news, including companies slashing inhaler costs and new hope for the UK life sciences sector.